schizandrin b has been researched along with Insulin Resistance in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, M; Ma, R; Wang, X; Wu, L; Zhan, Y; Zhang, Y | 1 |
| Jung, DY; Jung, MH; Kim, JH; Lee, H | 1 |
2 other study(ies) available for schizandrin b and Insulin Resistance
| Article | Year |
|---|---|
Schisandrin B ameliorates non-alcoholic liver disease through anti-inflammation activation in diabetic mice.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Body Weight; Cyclooctanes; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin Resistance; Lignans; Lipid Metabolism; Lipids; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Polycyclic Compounds; RNA, Messenger; Sterol Regulatory Element Binding Protein 1 | 2022 |
Antidiabetic effect of gomisin N via activation of AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cyclooctanes; Diabetes Mellitus; Dose-Response Relationship, Drug; Enzyme Activation; Female; Hypoglycemic Agents; Insulin; Insulin Resistance; Lignans; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle, Skeletal; Organelle Biogenesis; Polycyclic Compounds | 2017 |